miR-200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Resistance to BRAF inhibitors (BRAFi) is one of the major challenges for targeted therapies for BRAF-mutant melanomas. However, little is known about the role of microRNAs in conferring BRAFi resistance. Herein, we demonstrate that miR-200c expression is significantly reduced whereas miR-200c target...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pigment Cell Melanoma Res
Autors principals: Liu, Shujing, Tetzlaff, Michael T., Wang, Tao, Yang, Ruifeng, Xie, Lin, Zhang, Gao, Krepler, Clemens, Xiao, Min, Beqiri, Marilda, Xu, Wei, Karakousis, Giorgos, Schuchter, Lynn, Amaravadi, Ravi K., Xu, Weiting, Wei, Zhi, Herlyn, Meenhard, Yao, Yuan, Zhang, Litao, Wang, Yingjie, Zhang, Lin, Xu, Xiaowei
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4597606/
https://ncbi.nlm.nih.gov/pubmed/25903073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12379
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars